The role of inflammatory mediators in epilepsy: Focus on developmental and epileptic encephalopathies and therapeutic implications.
Chemokine
Cytokine
Epilepsy
Neuroinflammation
Steroid
West syndrome
Journal
Epilepsy research
ISSN: 1872-6844
Titre abrégé: Epilepsy Res
Pays: Netherlands
ID NLM: 8703089
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
14
12
2020
revised:
28
01
2021
accepted:
16
02
2021
pubmed:
16
3
2021
medline:
26
2
2022
entrez:
15
3
2021
Statut:
ppublish
Résumé
In recent years, there has been an increasing interest in the potential involvement of neuroinflammation in the pathogenesis of epilepsy. Specifically, the role of innate immunity (that includes cytokines and chemokines) has been extensively investigated either in animal models of epilepsy and in clinical settings. Developmental and epileptic encephalopathies (DEE) are a heterogeneous group of epileptic disorders, in which uncontrolled epileptic activity results in cognitive, motor and behavioral impairment. By definition, epilepsy in DEE is poorly controlled by common antiepileptic drugs but may respond to alternative treatments, including steroids and immunomodulatory drugs. In this review, we will focus on how cytokines and chemokines play a role in the pathogenesis of DEE and why expanding our knowledge about the role of neuroinflammation in DEE may be crucial to develop new and effective targeted therapeutic strategies to prevent seizure recurrence and developmental regression.
Identifiants
pubmed: 33721708
pii: S0920-1211(21)00041-3
doi: 10.1016/j.eplepsyres.2021.106588
pii:
doi:
Substances chimiques
Chemokines
0
Cytokines
0
Immunomodulating Agents
0
Inflammation Mediators
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
106588Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.